European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms

Launched by UNIVERSITY OF FLORENCE · Aug 18, 2024

Keywords

ClinConnect Summary

The European Registry for Transperineal Laser Ablation of Prostate (TPLA) is a study designed to evaluate the effectiveness and safety of a laser treatment for men experiencing bothersome urinary symptoms due to an enlarged prostate, a condition known as benign prostatic hyperplasia. This treatment aims to relieve symptoms without needing further surgery. The researchers will collect information from patients about their experiences and outcomes after the procedure to understand how well it works over time.

To be eligible for this study, participants need to be at least 18 years old and have moderate to severe urinary symptoms, as determined by a specific scoring system. They should also have a prostate size of at least 30 milliliters. Participants will be monitored for safety and effectiveness of the treatment, and they will be asked to report on their urinary symptoms and overall well-being. It's important to note that individuals with certain conditions, such as prostate cancer or previous prostate surgeries, will not be able to join the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years;
• • Prostate volume ≥ 30 mL;
• • Moderate-to-severe LUTS according to International Prostatic Symptoms Score (IPSS ≥8)
• • Consent to participate;
• Exclusion Criteria:
• • Absence of consent;
• • Subsequent withdrawal of consent;
• • Diagnosis or suspicion of prostate cancer at multiparametric magnetic resonance
• • Documented bladder impaired contractility
• • Urethral stenosis
• • Previous prostate surgery